Original article

Incidence, mortality and survival analysis of small intestine cancer in Shanghai population-based study from 2002 to 2016

Expand
  • Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China

Received date: 2023-04-17

  Online published: 2023-08-18

Abstract

Objective: To investigate the incidence, mortality and survival of small intestine cancer in Shanghai from 2002 to 2016. Methods: Data of new small intestine cancer cases and deaths from 2002 to 2016 were obtained from the population-based cancer registry and Vital Statistics System of Shanghai Municipal Center for Disease Control and Prevention. The incidence and mortality of small intestine cancer stratified by year of diagnosis or death, gender and age-group were analyzed. Cases or deaths, proportion, crude rate, age-specific rate, age-standardized rate and others were calculated. Trends of cases or deaths, crude rate, age-specific rate and age-standardized rate of incidence and mortality with follow-up information were estimated. The annual percent change (APC) of age-standardized rates of incidence and mortality was estimated by Joinpoint analysis. The new cases and proportions with selected diagnostic character of small intestine cancer in different diagnosis years were also calculated. Age-standardized rates were calculated using Segi’s 1960 world standard population. The 1- to 5-year observed survival rates were calculated based on the life table. The probabilities of surviving from 0 to 99 years old were estimated according to the Elandt-Johnson model, and then the cumulative expected survival rates were calculated according to the Ederer Ⅱ method. Finally, the 1- to 5-year relative survival rates were calculated. Results: The age-standardized rates of incidence and mortality of small intestine cancer were stable in Shanghai from 2002 to 2016. The new average cases and deaths of small intestine cancer were 280 and 174 per year in Shanghai. The crude rate of incidence was 2.02/105, and the age-standardized rate was 0.96/105. The crude rate of mortality was 1.25/105, and the age-standardized rate was 0.54/105. The age-standardized rates of incidence and mortality in males were higher than those in females. The age-specific cases or deaths and rates of incidence and mortality increased with aging. Duodenum cancer was the dominant anatomical site. Adenocarcinoma was the most histopathological type, and the proportion of gastrointestinal stromal tumors was increasing. The 5-year observed survival rate of small intestine cancer diagnosed from 2002 to 2013 was 36.34% in Shanghai, and the 5-year relative survival rate was 39.98%. All survival rates of male were lower than those of female. The 5-year observed and relative survival rates were stable. And those decreased with the increase of diagnostic years and stages. Relative to other sites, the rates of the duodenum cancer were the lowest. Relative to other histopathological types, those of gastrointestinal stromal tumors were the highest. Conclusions: The diagnostic level of small intestine cancer has been improved in Shanghai, continuously. But the survival rates have not been improved with the times. The proportion of stage Ⅰ was low and without improvement for a long time. This study provides useful information to further research, control and prevention of small intestine cancer. Improvement of the surveillance and research on small intestine cancer will help to promote more efficient control and prevention strategies then decrease cancer burden.

Cite this article

WU Chunxiao, GU Kai, PANG Yi, WANG Chunfang, SHI Liang, XIANG Yongmei, GONG Yangming, DOU Jianming, SHI Yan, FU Chen . Incidence, mortality and survival analysis of small intestine cancer in Shanghai population-based study from 2002 to 2016[J]. Journal of Surgery Concepts & Practice, 2023 , 28(03) : 240 -248 . DOI: 10.16139/j.1007-9610.2023.03.011

References

[1] ASSUMP??O P, KHAYAT A, ARAúJO T, et al. The small bowel cancer incidence enigma[J]. Pathol Oncol Res, 2020, 26(2):635-639.
[2] 国家癌症中心. 中国肿瘤登记工作指导手册(2016)[M]. 北京: 人民卫生出版社, 2016:59-75.
[2] National Cancer Center. Chinese guideline for cancer re-gistration(2016)[M]. Beijing: People's Medical Publishing House, 2016:59-75.
[3] PARKIN D M, CHEN V W, FERLAY J, et al. Comparability and quality control in cancer registration. IARC Technical Report No.19[M]. Lyon: IARC Press,1994.
[4] 上海市疾病预防控制中心. 上海市恶性肿瘤发病率、死亡率和生存率(2001—2012)[M]. 上海: 上海科学普及出版社, 2017:1-6.
[4] Shanghai Municipal Center For Disease Control & Prevention. Cancer incidence, mortality and survival rates in Shanghai (2001—2012)[M]. Shanghai: Shanghai General Science Press, 2017:1-6.
[5] BOSMAN F T, CARNEIRO F, HRUBAN R H, et al. WHO classification of tumours of the digestive system, 4th Ed, Volume 3[M]. Lyon: IARC Press, 2010.
[6] 卢伟, 郑莹. 肿瘤命名与编码[M]. 上海: 第二军医大学出版社, 2011.
[6] LU W, ZHENG Y. Tumor nomenclature and coding[M]. Shanghai: Second Military Medical University Press, 2011.
[7] SEGI M. Cancer mortality for selected sites in 24 countries (1950-1957)[M]. Sendai, Japan: Tohoku University School of Medicine,1960.
[8] 安澜, 郑荣寿, 张思维, 等. Elandt-Johnson模型推算完全寿命表方法学原理及其在中国人群寿命表中的应用[J]. 中国卫生统计, 2019, 36(5):768-773.
[8] AN L, ZHENG R S, ZHANG S W, et al. The principle of Elandt-Johnson Model for calculating the complete life table and it’s application in the life table of Chinese population[J]. Chin J Health Stat, 2019, 36(5):768-773.
[9] ESTèVE J, BENHAMOU E, RAYMOND L. Statistical methods in cancer research. Volume Ⅳ. Descriptive epidemiology[J]. IARC Sci Publ, 1994, 128:1-302.
[10] Statistical Research and Applications Branch, National Cancer Institute. Joinpoint regression program, version 4.8.0.1[C]. April, 2020.
[11] KIM H J, FAY M P, FEUER E J, et al. Permutation tests for joinpoint regression with applications to cancer rates[J]. Stat Med, 2000, 19(3):335-351.
[12] 国家癌症中心. 2019中国肿瘤登记年报[M]. 北京: 人民卫生出版社, 2021:216-269.
[12] National Cancer Center. 2019 Chinese cancer registry annual report[M]. Beijing: People's Medical Publishing House, 2021:216-269.
[13] National Cancer Institute. Cancer stat facts: small intestine cancer[EB/OL]. [2023/3/25]. https://seer.cancer.gov/statfacts/html/smint.html.
[14] 吴春晓, 龚杨明, 顾凯, 等. 2016年上海市结肠直肠癌发病和死亡情况与2002—2016年间的变化趋势分析[J]. 外科理论与实践, 2021, 26(4):325-335.
[14] WU C X, GONG Y M, GU K, et al. Colorectal cancer incidence and mortality in Shanghai 2016 and trend analysis 2002—2016[J]. J Surg Concepts Pract, 2021, 26(4):325-335.
[15] WEISS N S, YANG C P. Incidence of histologic types of cancer of the small intestine[J]. J Natl Cancer Inst, 1987, 78(4):653-656.
[16] 吴春晓, 顾凯, 庞怡, 等. 2002—2016年上海市胃肠间质瘤发病和生存分析[J]. 肿瘤, 2022, 42(7):489-498.
[16] WU C X, GU K, PANG Y, et al. Incidence and survival analysis of gastrointestinal stromal tumors in Shanghai:a population-based study from 2002 to 2016[J]. Tumor, 2022, 42(7):489-498.
[17] SELLNER F. Investigations on the significance of the adenoma-carcinoma sequence in the small bowel[J]. Cancer, 1990, 66(4):702-715.
[18] LYNCH H T, LYNCH P M, LANSPA S J, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications[J]. Clin Genet, 2009, 76(1):1-18.
[19] JESS T, GAMBORG M, MATZEN P, et al. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies[J]. Am J Gastroenterol, 2005, 100(12):2724-2729.
[20] TOMASETTI C, VOGELSTEIN B. Cancer risk: role of environment-response[J]. Science, 2015, 347(6223),729-731.
[21] WU A H, YU M C, MACK T M. Smoking, alcohol use, dietary factors and risk of small intestinal adenocarcinoma[J]. Int J Cancer, 1997, 70(5):512-517.
[22] BENNETT C M, COLEMAN H G, VEAL P G, et al. Lifestyle factors and small intestine adenocarcinoma risk: a systematic review and meta-analysis[J]. Cancer Epidemiol, 2015, 39(3):265-273.
[23] BOFFETTA P, HASHIBE M. Alcohol and cancer[J]. Lancet Oncol, 2006, 7(2):149-156.
[24] SEITZ H K, STICKEL F. Molecular mechanisms of alcohol-mediated carcinogenesis[J]. Nat Rev Cancer, 2007, 7(8):599-612.
[25] BOYD N, DANCEY J E, GILKS C B, et al. Rare cancers: a sea of opportunity[J]. Lancet Oncol, 2016, 17(2):e52-e61.
[26] MATHOULIN-PéLISSIER S, PRITCHARD-JONES K. Evidence-based data and rare cancers: the need for a new methodological approach in research and investigation[J]. Eur J Surg Oncol, 2019, 45(1):22-30.
Outlines

/